Clinical trial NCT02062346: Endothelin Antagonism in ANCA Vasculitis
Official title: The Vascular Effects of Endothelin Receptor Antagonism in Systemic Vasculitis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Vasculitis
Keywords: endothelin;
blood pressure;
vasculitis
Lead sponsor: University of Edinburgh
Sponsor class: OTHER
Collaborators: name: British Heart Foundation
First posted: 2014-02-13
Enrollment: 64
Sex: ALL
Minimum age (years): 18
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: Patients with vasculitis commonly develop cardiovascular disease. The reasons for this are not clear and is not adequately treated with current drugs. It is thus understand the reasons why patients with vasculitis develop cardiovascular disease in order to develop new drugs to reduced this risk.

Endothelin is a chemical produced by blood vessels that contributes to the development of hypertension and cardiovascular disease Higher than normal levels of endothelin are seen in patients with vasculitis but how this contributes to cardiovascular disease in patients with vasculitis is not clear. By using drugs that block the effects of endothelin ('endothelin receptor antagonists') the investigators can hopefully reduce the risk of cardiovascular disease in patients with vasculitis. The purpose of the study is to ascertain if endothelin receptor antagonists improve blood vessel function in patients with vasculitis.

Detailed description: Vasculitis patients and healthy controls matched for age, sex will be enrolled into the study. Patients will attend for 4 study days \>1 week apart, whereas controls will attend for single day. Circulating Mφ and other immune cells will be confirmed using FACS prior each study.

Study 1 Both patients and control will attend for visit 1: assessment of vascular function using forearm plethysmography as part of case control study.

Vasculitis patients will then attend for visits 2, 3 \& 4 as part of randomised three way crossover study (randomised \& infusions given in a double-blind method): comparison of the effects of selective ETA receptor antagonism (BQ123; 1000nmol/min for 15min iv), mixed ETA/B antagonism (BQ123/788; 1000 nmol/min \& 300 nmol/min for 15 min), and placebo on systemic haemodynamics.

Eligibility criteria: Inclusion Criteria:

* Male or female
* Age 18 years and over
* Body mass index ≤35
* Normal serum albumin

Exclusion Criteria:

* Subject with diabetes or current smoking or chronic kidney disease (eGFR \<60ml/min)
* Subject with pre-existing cardiovascular disease
* Subject is below the age of legal consent, or is mentally or legally incapacitated
* History of multiple and/or severe allergic reactions to drugs (including study drugs)
* The subject has donated blood (450 ml) within the last 4 weeks
* Past or present drug or alcohol abuse including intravenous drug abuse at any time
* Participation in another clinical trial within 1 month
* Considered to be at high risk of HIV or hepatitis B
* Women of child-bearing potential (only women who are post-menopausal or surgically-sterilised will be included in the study)

Primary outcomes:
measure: Study 1 - forearm blood flow
timeFrame: 20mins
measure: Study 2 - pulse wave velocity
timeFrame: 4 hours
Secondary outcomes:
measure: Study 1 - tPA release
timeFrame: 20min
measure: Study 1 - baseline pulse wave velocity
timeFrame: Baseline
measure: Study 2 - tPA release
timeFrame: 4 hours
Other outcomes:
Locations:
city: Edinburgh
country: United Kingdom
facility: University of Edinburgh
state: Midlothian
city: Edinburgh
country: United Kingdom
facility: University of Edinburgh
Study officials:
affiliation: University of Edinburgh
name: Neeraj Dhaun
role: PRINCIPAL_INVESTIGATOR
References: